生产企业：CanSino Biologics Inc.
PCV-24 (PCV24) is CanSino Biologics Inc.'s investigational 24-valent pneumococcal polysaccharide conjugate vaccine that utilizes a CRM197/tetanus toxoid dual-carrier technology platform; it is intended to help prevent infectious diseases caused by 24 pneumococcal serotypes and initiated Phase I/II clinical trials in May 2026.
PCV-24 (PCV24) is CanSino Biologics Inc.'s investigational 24-valent pneumococcal polysaccharide conjugate vaccine that utilizes a CRM197/tetanus toxoid dual-carrier technology platform; it is intended to help prevent infectious diseases caused by 24 pneumococcal serotypes and initiated Phase I/II clinical trials in May 2026.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
